Valérie de Haas1, Nofisat Ismaila2, Anjali Advani3, Daniel A Arber4, Raetasha S Dabney5, Dipti Patel-Donelly6, Elizabeth Kitlas7, Rob Pieters1, Ching-Hon Pui8, Kendra Sweet9, Ling Zhang9. 1. 1 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. 2. 2 American Society of Clinical Oncology, Alexandria, VA. 3. 3 Cleveland Clinic, Cleveland, OH. 4. 4 University of Chicago Medical Center, Chicago, IL. 5. 5 Keesler Medical Center, Ocean Springs, MS. 6. 6 Virginia Cancer Specialists, Fairfax, VA. 7. 7 The Leukemia and Lymphoma Society, Rye Brook, NY. 8. 8 St Jude Children's Research Hospital, Memphis, TN. 9. 9 Moffitt Cancer Center, Tampa, FL.
Abstract
PURPOSE: The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The CAP-ASH guideline on initial diagnostic work-up of AL was reviewed for developmental rigor by methodologists. Then, an ASCO Endorsement Expert Panel updated the literature search and reviewed the content and recommendations. RESULTS: The ASCO Expert Panel determined that the recommendations from the guideline, published in 2016, are clear, thorough, and based on the most relevant scientific evidence. ASCO fully endorsed the CAP-ASH guideline on initial diagnostic work-up of AL and included some discussion points according to clinical practice and updated literature. CONCLUSION: Twenty-seven guideline statements were reviewed. Some discussion points were included to better assess CNS involvement in leukemia and to provide novel insights into molecular diagnosis and potential markers for risk stratification and target therapy. These discussions are categorized into four sections: (1) initial diagnosis focusing on basic diagnostics and determination of risk parameters, (2) molecular markers and minimal residual disease detection, (3) context of referral to another institution with expertise in the management of AL, and (4) reporting and record keeping for better outlining and follow-up discussion. Additional information is available at: www.asco.org/hematologic-malignancies-guidelines .
PURPOSE: The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The CAP-ASH guideline on initial diagnostic work-up of AL was reviewed for developmental rigor by methodologists. Then, an ASCO Endorsement Expert Panel updated the literature search and reviewed the content and recommendations. RESULTS: The ASCO Expert Panel determined that the recommendations from the guideline, published in 2016, are clear, thorough, and based on the most relevant scientific evidence. ASCO fully endorsed the CAP-ASH guideline on initial diagnostic work-up of AL and included some discussion points according to clinical practice and updated literature. CONCLUSION: Twenty-seven guideline statements were reviewed. Some discussion points were included to better assess CNS involvement in leukemia and to provide novel insights into molecular diagnosis and potential markers for risk stratification and target therapy. These discussions are categorized into four sections: (1) initial diagnosis focusing on basic diagnostics and determination of risk parameters, (2) molecular markers and minimal residual disease detection, (3) context of referral to another institution with expertise in the management of AL, and (4) reporting and record keeping for better outlining and follow-up discussion. Additional information is available at: www.asco.org/hematologic-malignancies-guidelines .
Authors: E Manara; V Bisio; R Masetti; V Beqiri; R Rondelli; G Menna; C Micalizzi; N Santoro; F Locatelli; G Basso; M Pigazzi Journal: Leukemia Date: 2013-11-14 Impact factor: 11.528
Authors: Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan Journal: Nat Genet Date: 2016-10-24 Impact factor: 38.330
Authors: Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi Journal: Blood Date: 2010-01-07 Impact factor: 22.113
Authors: E Clappier; N Grardel; M Bakkus; J Rapion; B De Moerloose; P Kastner; A Caye; J Vivent; V Costa; A Ferster; P Lutz; F Mazingue; F Millot; D Plantaz; G Plat; E Plouvier; M Poirée; N Sirvent; A Uyttebroeck; K Yakouben; S Girard; N Dastugue; S Suciu; Y Benoit; Y Bertrand; H Cavé Journal: Leukemia Date: 2015-06-08 Impact factor: 11.528
Authors: Michael M Boyiadzis; Ivan Aksentijevich; Daniel A Arber; John Barrett; Renier J Brentjens; Jill Brufsky; Jorge Cortes; Marcos De Lima; Stephen J Forman; Ephraim J Fuchs; Linda J Fukas; Steven D Gore; Mark R Litzow; Jeffrey S Miller; John M Pagel; Edmund K Waller; Martin S Tallman Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751